research use only
Cat.No.S4307
| Related Targets | Dehydrogenase HSP Transferase P450 (e.g. CYP17) PDE phosphatase PPAR Vitamin Carbohydrate Metabolism Mitochondrial Metabolism |
|---|---|
| Other Thioredoxin Reductase Inhibitors | TRi-1 |
|
In vitro |
DMSO
: 100 mg/mL
(147.38 mM)
Ethanol : 100 mg/mL Water : Insoluble |
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.
| Molecular Weight | 678.48 | Formula | C20H34AuO9PS |
Storage (From the date of receipt) | |
|---|---|---|---|---|---|
| CAS No. | 34031-32-8 | Download SDF | Storage of Stock Solutions |
|
|
| Synonyms | SKF39162 | SMILES | CCP(CC)CC.CC(=O)OCC1C(C(C(C(O1)[S-])OC(=O)C)OC(=O)C)OC(=O)C.[Au+] | ||
Read more about storage stability stock solution CAS number SMILES
| Targets/IC50/Ki |
TrxR
(Cell-free assay) 88 nM
|
|---|---|
| In vitro |
Auranofin (Ridaura, SKF-39162) is an inhibitor of thioredoxin reductase (TrxR) with IC50 of 88 nM for purified H. pylori TrxR in cell-free assay. |
| In vivo |
This compound is a small molecule inhibitor of NONO that suppressed GBM tumor growth in an orthotopic xenograft model in mice. |
References |
|
(data from https://clinicaltrials.gov, updated on 2026-08-19)
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT06805656 | RECRUITING | Hiv; HIV I Infection |
Federal University of São Paulo |
2026-07-15 | PHASE2 |
| NCT01737502 | COMPLETED | Extensive Stage Small Cell Lung Carcinoma; Lung Adenocarcinoma; Recurrent Non-Small Cell Lung Carcinoma; Recurrent Small Cell Lung Carcinoma; Squamous Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer; Stage IIIB Non-Small Cell Lung Cancer; Stage IV Non-Small Cell Lung Cancer |
Mayo Clinic |
2014-05-14 | PHASE1; PHASE2 |
| NCT02736968 | COMPLETED | Amoebic Dysentery; Giardiasis |
National Institute of Allergy and Infectious Diseases (NIAID) |
2016-11-06 | PHASE2 |
| NCT03456700 | TERMINATED | Ovarian Serous Tumor; Recurrent Ovarian Carcinoma |
Mayo Clinic |
2018-03-30 | PHASE2 |
| NCT02961829 | COMPLETED | Chronic Infection; HIV |
Federal University of São Paulo |
2015-07 | |
| NCT02770378 | COMPLETED | Glioblastoma |
University of Ulm |
2016-11 | PHASE1; PHASE2 |
Read more about Clinical Trials
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.